Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial
Clinical trial NCT04971005 · TERMINATED
Trial details
- NCT number
- NCT04971005
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-27
- Primary completion
- 2022-02-04
- Enrollment
- 1
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.